We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efectos pleiotrópicos del paricalcitol, más allá del metabolismo óseo-mineral.
- Authors
Egido, Jesús; Martínez-Castelao, Alberto; Bover, Jordi; Praga, Manuel; Vicente Torregrosa, José; Fernández-Giráldez, Elvira; Solozábal, Carlos
- Abstract
Secondary hyperparathyroidism (SHPT) is a common complication in patients with chronic kidney disease (CKD) that is characterised by elevated parathyroid hormone (PTH) levels and a series of bone-mineral metabolism anomalies. In patients with SHPT, treatment with paricalcitol, a selective vitamin D receptor activator, has been shown to reduce PTH levels with minimal serum calcium and phosphorus variations. The classic effect of paricalcitol is that of a mediator in mineral and bone homeostasis. However, recent studies have suggested that the benefits of treatment with paricalcitol go beyond PTH reduction and, for instance, it has a positive effect on cardiovascular disease and survival. The objective of this study is to review the most significant studies on the so-called pleiotropic effects of paricalcitol treatment in patients with CKD.
- Publication
Nefrologia, 2016, Vol 36, Issue 1, p10
- ISSN
0211-6995
- Publication type
Article
- DOI
10.1016/j.nefro.2015.11.003